Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Other Current Assets

Current assets not reported separately, such as prepaid expenses.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Other Current Assets · Q1 FY2026 · quarter ended Mar 2026

Other current assets rises 725.0% from a year ago

Other current assets stood at $33K at the end of Q1 FY2026, up 725.0% from a year earlier and up 22.2% from the prior quarter.

Context

  • Other current assets amounted to 0.9% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
  • Other current assets increased in 1 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether other current assets keeps rising in the next quarterly balance sheet after a +725.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33K+22.2% QoQ
Last fiscal yearDec 2025
$27K— YoY
Year agoMar 2025
$4K+725.0% since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+725.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
27K USD
Year-over-year change
—

Other Current Assets vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's Mar 2026 other current assets of $33K is the lowest of the 8 companies compared; the peer median is $1.9M.
  • Its year-over-year change of +725.0% is the 4th highest of 8, against a peer median of +534.3%.
  • Other current assets amounts to 0.9% of total assets for PLYX, versus a peer median of 1.4%.
PLYX Competitors Peer median
Other Current Assets for PLYX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LYELLyell Immunopharma, Inc.Mar 2026$13.28M +1328099900.0%+7.2%3.8%
JBIOJade Biosciences, Inc.Mar 2026$7.22M +754.7%—2.3%
FHTXFoghorn Therapeutics Inc.Mar 2026$3.18M -34.1%-8.1%1.4%
ANTXAN2 Therapeutics, Inc.Mar 2026$1.9M +534.3%-26.1%2.2%
CBIOCrescent Biopharma, Inc.Mar 2026$1.37M +1643.2%—0.7%
KLRSKalaris Therapeutics IncMar 2026$861K +23.9%+196.2%0.8%
PTHSPelthos Therapeutics Inc.Mar 2026$545K -24.6%—0.4%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$33K +725.0%—0.9%
Peer median (excluding PLYX) $1.9M+534.3%-0.5%1.4%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.